- Home
- SPHL vs NLSP Comparison
SPHL vs NLSP Comparison
Compare SPHL & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- NLSP
- Stock Information
- Founded
- SPHL 2002
- NLSP 2015
- Country
- SPHL Singapore
- NLSP Switzerland
- Employees
- SPHL N/A
- NLSP N/A
- Industry
- SPHL Homebuilding
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- NLSP Health Care
- Exchange
- SPHL Nasdaq
- NLSP Nasdaq
- Market Cap
- SPHL 6.1M
- NLSP 5.8M
- IPO Year
- SPHL 2024
- NLSP 2021
- Fundamental
- Price
- SPHL $0.51
- NLSP $2.30
- Analyst Decision
- SPHL
- NLSP
- Analyst Count
- SPHL 0
- NLSP 0
- Target Price
- SPHL N/A
- NLSP N/A
- AVG Volume (30 Days)
- SPHL 133.9K
- NLSP 410.5K
- Earning Date
- SPHL 02-21-2025
- NLSP 06-17-2025
- Dividend Yield
- SPHL N/A
- NLSP N/A
- EPS Growth
- SPHL N/A
- NLSP N/A
- EPS
- SPHL N/A
- NLSP N/A
- Revenue
- SPHL $6,456,601.00
- NLSP N/A
- Revenue This Year
- SPHL N/A
- NLSP N/A
- Revenue Next Year
- SPHL N/A
- NLSP N/A
- P/E Ratio
- SPHL N/A
- NLSP N/A
- Revenue Growth
- SPHL N/A
- NLSP N/A
- 52 Week Low
- SPHL $0.35
- NLSP $1.30
- 52 Week High
- SPHL $7.80
- NLSP $18.39
- Technical
- Relative Strength Index (RSI)
- SPHL N/A
- NLSP 65.15
- Support Level
- SPHL N/A
- NLSP $1.58
- Resistance Level
- SPHL N/A
- NLSP $2.39
- Average True Range (ATR)
- SPHL 0.00
- NLSP 0.23
- MACD
- SPHL 0.00
- NLSP 0.02
- Stochastic Oscillator
- SPHL 0.00
- NLSP 89.29
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.